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Many different drugs have been tried for treating non-gonococcal urethritis (NGU) with varying degrees of success; this report describes an attempt to evaluate the effect of Sigmamycin at two different dosage levels.
Sigmamycin is a 2 :1 combination of the antibiotics tetracycline hydrochloride and oleandomycin phosphate, and the claim has been made that this combination exhibits a synergistic action, so that the two drugs together are more potent than the sum of the individual components. To test this claim two separate trial series of patients were treated, using a small dose for a minimum time in the first, and a large dose for a slightly longer period in the second. In each series controls were used and the drug or a placebo was administered by the double-blind method to a total of 200 white male patients with non-gonococcal urethritis. Neither patients nor medical staff knew who received antibiotic or placebo, and the key to the coding used was retained by the suppliers of the drug until the completion of each half of the trial.
A certain amount of selection of patients was used, those giving a history of gonorrhoea or NGU within a year, those who had recently had treatment, and those who were unlikely to attend for follow up being excluded from the trial.
* Received for publication May 25, 1959. 
Method
The patients were first seen in the ordinary clinic, the history was taken, a full examination was carried out and the preliminary diagnosis of non-gonococcal urethritis was confirmed by examination of an urethral smear. Cultures were set up to exclude gonorrhoea and to reveal any bacteria present in the discharge. In addition, a fresh wet preparation and culture were examined routinely for Trichomonas vaginalis. Finally, the result of the two-glass test was carefully recorded and blood was taken for serological tests for syphilis. Patients were seen again the following morning whenever possible, for an early morning test (E.M.S.) before urinating. This included urethral scraping of the terminal urethra and fossa navicularis, and a further search for T. vaginalis in a wet preparation and by culture. The two-glass test was then carried out and recorded. Anyone who on first attending had held his urine overnight or for 8 hours or more was excused attending for an E.M.S. the next morning.
Contact slips were issued, and each patient was exhorted to send along his recent sex contacts. Finally, each patient was handed a bottle containing the capsules, taken at random from the cupboard and bearing only a label with a number on it and instructions how to take the drug. Alcohol and sexual intercourse were banned during the period of attendance at the clinic.
In order to standardize the follow-up tests, the first hundred patients were asked to attend in the early morning before urinating. In this way a two-glass test could be carried out as a standard procedure on the first urine specimen of the day, and a truer indication could be obtained of the response to treatment. As far as possible, 223 one examiner only recorded the test results. This procedure was modified for the second hundred when it was discovered that many patients, on close questioning, had not in fact been able to hold their urine, so invalidating the test. Also, the quantity of the first spe-imen could vary between a few ml. and a full glass, whatever directive was issued. Accordingly, each of the second batch of patients was issued with a sterile 2-oz. bottle for the first specimen and was told to conduct the two-glass test himself on rising on the day of attendance at the clinic, using a convenient large bottle for the second specimen.
At the end of the fourth or fifth week, prostatic massage was carried out if signs of urethritis had abated. Wet preparations of the prostatic secretion were examined for pus cells and the T. vaginalis, and a stained preparation was read later. Those patients who had developed chronic prostatitis were treated appropriately.
Re-treatment with known drugs had to be resorted to when there was no response over a period of several weeks, or when complications (e.g. cystitis) supervened. The number of weeks elapsing before re-treatment in the "no-response" cases varied according to the type of patient. Ideally, they were left for 8 weeks without specific treatment and placebos such as vitamins and Mist. pot. cit. were administered. This period was chosen because Gartman and Leibovitz (1955) claimed that there was a spontaneous cure without treatment in 58 5 per cent. of cases within 8 weeks. However, some more anxious patients had to be re-treated earlier than the eighth week if their condition did not seem to be improving. Those who had recurrences were treated appropriately, according to the severity of the recurrence, and the cause was noted.
Each patient was seen weekly until a fortnight after their two specimens of urine were quite clear, fortnightly for 8 weeks, and at the end of 12 weeks.
Results
The information collected during the trial in respect of history, aetiology, symptoms, signs, and subjective and objective response to therapy was later transferred to punch cards (Fig. 1) .
The dose used in the first hundred patients was 100 mg. Sigmamycin 6-hrly for 4 days, and for the second hundred, 500 mg. Sigmamycin 6-hrly for 5 days. The placebo used was lactose in each series. A subjective response was indicated by the patient's own observations of when his symptoms decreased and finally disappeared, and thus was recorded separately from the clinical findings. The objective (Fig. 3) . A gradual response might take up to 8 weeks. Any whose specimens showed little or no improvement for 8 weeks were said to show no response, as did also those whose condition worsened after taking the capsules, and who therefore had to be re-treated with other drugs (Fig. 4) 3)
'5) Single men outnumbered married men except in the second group ofcontrols (Table II) . However, the total incidence shows that single men do not significantly outnumber married men contracting NGU. The chief symptom was urethral discharge in 93 * 5 per cent., and about half of these patients also (48 per cent.) complained of dysuria. A few patients who came for routine "check up" without any symptoms were found to have NGU. Again, there was an even distribution throughout controls and treated cases (Table IJI) . (Table  VII) , the proportion of non-gonococcal to gonococcal infections being about equal.
The subjective response to treatment indicated by the patient's reply to the question, "Has your discharge ceased ?" is shown in Table VIIIA ; roughly the same number (29 and 28) in the two treated groups A5 and A2 were better within a week, whereas only seventeen and nine, respectively, of the two control groups were better. Table VIIIB shows the numbers in each of the categories mentioned previously, and in addition the total number followed-up for a sufficient period to be able to reach a conclusion.
It is evident that, in the first series, thirteen of the treated patients and ten of the controls claimed that their discharge had ceased after one week, when, in of the controls who still had urethritis after 8 weeks.
Of those who had recurrences, the Table shows that the majority (22 per cent. and 15 * 5 per cent. of those followed up in Groups I and 2 respectively) occurred after complete cure rather than during a gradual response, which is what one might expect for the treated group. There seemed to be fewer recurrences altogether in the control groups, presumably because fewer were cured. A recurrence following complete "cure" seemed slightly less likely if the larger dose of Sigmamycin was used.
If Table VIlIB is now considered, it is very interesting to discover that, taking the whole 8-week period used for measuring the response, i.e. those responding gradually added to those responding immediately, the successes were 83 per cent. of cases treated with a small dose and 93 per cent. of the cases treated with a larger dose, and that the two control groups came out remarkably close together (around the 60 per cent. level). This indicates that this proportion, less recurrences, would be symptom-free without any treatment at the end of 8 weeks. The improvement factor is thus about 23 per cent. in the small dose series over an 8-week period, and 32 per cent. for the larger dose series, a significant difference. There seems to be slightly more likelihood of a recurrence at some stage during the 8 weeks following a small dose of the drug than after the use of a larger dose. The average recurrence rate for the two control groups is 8-5 per cent. (Table VIIID) . The reasons for recurrences are analysed in Table IX (opposite); alcohol is seen to be the predominant factor, closely followed by those in whom no history could be obtained. Sexual intercourse caused a recurrence in five out of 26 recurrences.
Chronic prostatitis was the commonest complication and a few patients developed cystitis, notably in the control groups ( No troublesome side-effects were noted, but the incidence of diarrhoea was greater in the treated groups (Table XI) . Finally, Table XII gives the bacteriological pattern of the urethra before treatment and that of the prostatic secretion after resolution of the urethritis. The staphylococcus was grown in most (Table VIIID) .
It is much more desirable from the patient's point of view, and also from that of minimizing the chance of spread of infection, to obtain a quick cure, and taking a 7-day period, the cure rate is 71 per cent. using a large dose and only 39 per cent. using a small dose ( Table VllIc) . The first figure is close to that quoted by Mayne (1957) , who found a 70 per cent. cure rate in treating the abacterial type of NGU with tetracycline. This, together with the low cure rate of 39 per cent. using a small dose, indicates that synergism between the two mixed antibiotics does not exist, and that the activity of Sigmamycin is presumably that of its most active constituent.
Of the non-treated controls, about 60-5 per cent. recover within 8 weeks, but some 8-5 per cent. are liable to have recurrences during that time. Thus,
